Thymogen Dosage: What the Research Shows

There is no modern, clinically validated dose for Thymogen. The dose most often cited online traces back to Soviet- and Russian-era pharmaceutical practice — roughly 100 mcg subcutaneously or intramuscularly once daily in short 3-10 day courses, or an intranasal-drop formulation. Below is that convention, the reconstitution and syringe-unit math, and an honest account of why a 20 mg research vial does not line up with a microgram-scale historical dose.

Thymogen is the synthetic dipeptide L-Glu-L-Trp (Glu-Trp, or EW) from the Russian "peptide bioregulator" research program associated with Vladimir Khavinson. Its studied efficacy sits in preclinical work — rodent and in-vitro — and most of the human clinical history belongs to the thymus extract (Thymalin) it was isolated from, not the isolated synthetic dipeptide sold as a research chemical.

Research-context information only. Thymogen is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Quick Reference: Protocol

None of these figures come from a modern controlled trial. The ~100 mcg dose reflects the originator-era Russian pharmaceutical convention for the extract-derived drug, not a dose-finding study of the research-chemical dipeptide. The 20 mg vial that vendors sell is sized for lab aliquoting, not the microgram clinical dose — the two do not match, and that gap is the honest headline of any Thymogen dosing discussion. For the full Thymogen profile and vendor pricing, see our Thymogen peptide page.

Cycling Details

Russian-era sources describe Thymogen as a short-course agent — a 3-10 day run, sometimes repeated a few times a year, rather than continuous daily use. This mirrors the pulsed way Khavinson-program bioregulators were administered in their originators' work. No modern human study has tested any cycling schedule for the synthetic dipeptide, so "a few courses per year" is convention carried forward from the pharmaceutical era, not a validated protocol.

Routes of Administration

Subcutaneous or intramuscular injection is the route the originator literature describes for the injectable formulation after reconstituting the lyophilized powder.

• Sites: Abdomen or anywhere with subcutaneous fat (SC); larger muscle for IM
• Volume: ~0.01-0.02 mL at the 10 mg/mL dilution for a 100 mcg dose — an impractically small draw (see conversion note)
• Intranasal: The original Russian Thymogen also existed as a low-concentration nasal-drop formulation; the research-chemical lyophilized vial is not that product
• Note: No route has been validated for the synthetic dipeptide in a modern human trial; oral use is not described, as peptides are degraded in the gut

Reconstitution Quick Reference

Math: 20 mg / 2 mL = 10 mg/mL. At that concentration, 1 unit on a 100-unit insulin syringe (0.01 mL) holds 100 mcg — so the historical 100 mcg dose is a single, hard-to-measure unit. Diluting less concentrated (more BAC water) is the only way the microgram figures draw at a readable volume; the full walkthrough and vial-size comparisons are in the Thymogen Reconstitution Guide.

Community sources describe gentle swirling — not shaking — with storage at 2-8°C and use within 28 days.

Ready to buy? Compare verified vendors on our best Thymogen sources page, or browse all coupon codes for up to 50% off.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

The ~100 mcg figure is not a modern trial dose — it is a pharmaceutical-era convention, and it is worth being explicit about that.

Thymogen is the isolated synthetic piece of an extract. In a 1997 review, the originator group reported that the immunomodulatory dipeptide L-Glu-L-Trp was isolated from the natural calf-thymus peptide complex Thymalin by reversed-phase HPLC, and a pharmaceutical (Thymogen) was designed from the synthesized dipeptide, which they described as activating T-cell differentiation (Kuznik et al., 1997). The clinical-use history attached to that lineage largely belongs to the extract, Thymalin — not the isolated synthetic dipeptide a research vial contains.

The animal evidence used weight-based dosing, not the human microgram figure. A Khavinson-group study reported that the synthetic dipeptide L-Glu-L-Trp slowed aging markers and lowered spontaneous tumor incidence in rats — total tumor incidence about 1.5 times lower and hematopoietic malignancies about 3.4 times lower than controls, per the authors (Anisimov et al., 2000). Those were the originators' findings in a single-group rodent design; the doses were tied to animal body weight and do not translate into the 100 mcg human convention.

Why the numbers persist anyway: the 100 mcg dose is inherited from the injectable pharmaceutical formulation, while research-chemical vendors sell a 20 mg vial sized for the lab, not the clinic. The convention survives out of habit and product-lineage memory — not because a modern dose-response trial confirmed it. Framing the underlying gene-expression mechanism as settled would also overstate it: that model is a Khavinson-group hypothesis drawn largely from in-vitro work, not a proven human pathway.

Stacking Protocols

The Thymogen research literature studied the dipeptide as a single agent in rodents and cells, not as part of a stack, so there are no study-documented combinations.

Community sources occasionally describe combining Thymogen with other thymic or longevity peptides, but no controlled data supports any specific combination.

Side Effects & Safety

• No modern human safety data — there is no modern controlled trial of the synthetic dipeptide, so its human side-effect profile is genuinely unknown
• Injection-site reactions — the most commonly mentioned issue in community reports (mild redness or irritation)
• Originators' tolerability claims — Russian-era sources described the pharmaceutical form as well tolerated, but that is an uncontrolled single-group claim, not audited pharmacovigilance
• Extract-vs-synthetic gap — favorable clinical history largely belongs to the Thymalin extract, not the isolated research-chemical dipeptide
• Single-group evidence — most published data comes from one research program, which limits independent Western confirmation

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (100 units = 1 mL). Because the historical Thymogen dose is measured in micrograms while vials are 20 mg, the draw depends heavily on how much the vial is diluted.

Reconstitution A: 20 mg vial + 2 mL BAC water (10 mg/mL) — the concentrated standard, where 1 unit holds 100 mcg. Microgram doses draw at barely measurable volumes.

Reconstitution B: 20 mg vial + 4 mL BAC water (5 mg/mL) — more dilute, so the same microgram doses draw at larger, easier-to-read volumes.

These conversions reflect the dilutions documented in community reconstitution math. They report how the math is described, not a recommended dosing schedule.